Patents by Inventor John J. Masters

John J. Masters has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6693109
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: February 17, 2004
    Assignees: Eli Lilly and Company, Millennium Pharmaceuticals, Inc.
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20030171373
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: January 29, 2003
    Publication date: September 11, 2003
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Michael Paal, Gerd Ruhter, Kenneth J. Ruterbories, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Integrin antagonists
    Patent number: 6552079
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: April 22, 2003
    Assignee: Eli Lilly and Company
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6528534
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: July 6, 2001
    Date of Patent: March 4, 2003
    Assignees: Millennium Pharmaceuticals, Inc., Eli Lilly and Company
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Theo Schotten, Wolfgang Stenzel, Robert M. Scarborough
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Publication number: 20020013325
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Application
    Filed: July 6, 2001
    Publication date: January 31, 2002
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Theo Schotten, Wolfgang Stenzel, Robert M. Scarborough
  • Integrin antagonists
    Publication number: 20010034369
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Application
    Filed: May 15, 2001
    Publication date: October 25, 2001
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation
    Patent number: 6291469
    Abstract: This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): wherein Q, L, Ai, Bj, R0, R3, R10, m, n, p and q are as defined in the disclosure, which are useful in inhibiting of platelet aggregation.
    Type: Grant
    Filed: October 5, 1998
    Date of Patent: September 18, 2001
    Assignees: Eli Lilly and Company, COR Therapeutics Inc.
    Inventors: Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffrey T. Mullaney, Kenneth J. Ruterbories, Michael Paal, Gerd Ruhter, Robert M. Scarborough, Theo Schotten, Wolfgang Stenzel
  • Integrin antagonists
    Patent number: 6245809
    Abstract: Novel compounds, their salts and compositions related thereto having activity against mammalian integrins are disclosed. The compounds are useful in vitro or in vivo for preventing or treating thrombotic or restenotic disorders.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: June 12, 2001
    Assignees: Cor Therapeutics Inc., Eli Lilly & Company
    Inventors: Robert M. Scarborough, Mark Smyth, Ting Su, Matthew J. Fisher, Joseph A. Jakubowski, John J. Masters, Jeffry Bernard Franciskovich
  • Total synthesis of taxol and analogues thereof
    Patent number: 5488116
    Abstract: The present invention provides three basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogues of taxol and nortaxol.
    Type: Grant
    Filed: November 2, 1993
    Date of Patent: January 30, 1996
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, William G. Bornmann, Yves Queneau, Thomas V. Magee, Walter J. Krol, John J. Masters, David K. Jung